EUCTR2020-002790-94-SE进行中（未招募）1 期
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density – A Single Dose Randomized, Double Blind, Placebo-Controlled Phase 2 Positron Emission Tomography Study - PSIPET
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- SLSO
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria
- •Individuals eligible to be randomized in this protocol are those who meet all of the following criteria:
- •1. Are 20 to 65 years old at the time of written informed consent at the In-Person Screening visit
- •2. Are able to read, speak, and understand Swedish
- •3. Are able and willing to adhere to study requirements, including attending all study visits, preparatory and follow-up sessions, and completing all study evaluations
- •4. Are able to swallow capsules
- •5. Women of childbearing potential (WOCBP) must agree to practice an effective means of birth control throughout the duration of the study, from Screening through the Day 42 assessment
- •6. Meet ICD-10 criteria for a diagnosis of remitting major depressive disorder and are currently experiencing a major depressive episode of
- •a) at least a 30-day duration at the time of the Screening
- •b) less than 5 years at time of Screening
- •7. Have sustained moderate-severe depression symptoms at Screening and Baseline, as defined by a Screening MADRS total score = 22 and =30% and =7 point improvement (i.e. decrease) in MADRS total score from web-screening to screening visit (assuming 3 points on item 1 at web screening).
- •9. Have an identified support person
- •a. Agree to be driven/accompanied home (or to an otherwise safe destination) by the support person, or another responsible party, following dosing
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria
- •Individuals not eligible to be randomized in this protocol are those who meet any of the following criteria:
- •1.Women who are pregnant, as indicated by a positive urine pregnancy test at Screening or Baseline. Women who intend to become pregnant during the study or who are currently nursing.
- •2.Current depressive episode lasting >5 years
- •2. Unwilling or unable to discontinue formal psychotherapy
- •3. Ongoing antidepressant drug treatment
- •4. Have previously during the current episode received the following non-medication treatments:
- •a. deep brain stimulation (DBS)
- •b. vagus nerve stimulation (VNS)
- •5. Currently receiving electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS)
- •6. Unable or unwilling to discontinue any current medications that are known uridine diphosphate (UDP) or glucuronosyltransferase (UGT) enzyme modulators (eg valproate)
- •o Note: Any prohibited agents must have been stopped at least 5x the elimination half-life of the specific drug at the time of Baseline. See Appendix A for a full list of prohibited medications.
- •7. Report psychedelic substances use ever
- •o Note: Psychedelic substances include psilocybin, Lysergic acid diethylamide (LSD), mescaline (and natural products containing mescaline including peyote and San Pedro cactus), N,N-Dimethyltryptamine (DMT), natural products containing DMT including ayahuasca and 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), ibogaine, 2C compounds, 3,4-methylenedioxy- methamphetamine (MDMA), methylone or other psychedelics.
- •8. Have the following cardiovascular conditions:
- •a. coronary artery disease, congenital long QT syndrome (prior diagnosis), cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction (prior diagnosis);
- •b. tachycardia (defined as heart rate > 100 beats per minute);
- •c. a clinically significant Screening ECG abnormality (e.g., atrial fibrillation);
- •oNote: A QTcF interval > 450 milliseconds is considered a clinically significant ECG abnormality
- •d. artificial heart valve; or
- •e. any other significant current or history of cardiovascular condition, based on the clinical judgment of study physician, that would make a participant unsuitable for the study
- •9. At Screening or Baseline have elevated blood pressure as defined as:
- •a. Screening blood pressure SBP >135 mmHg or DBP > 85 mmHg on three separate readings; or
- •b. Baseline blood pressure SBP >140 mmHg or DBP > 90 mmHg on three separate readings
- •10. Have a history of stroke or Transient Ischemic Attack (TIA)
- •11. Have moderate to severe hepatic impairment, as indexed by a Child-Pugh score = 7
- •12. Have epilepsy
- •13. Have insulin-dependent diabetes
- •o Note: Participants who are taking oral hypoglycemic agent and have a history of hypoglycemia requiring medical intervention will be excluded
- •14. Are unable or unwilling to adhere to the following medication requirements:
- •a. Agree to suspend sildenafil (Viagra®), tadalafil, or similar medications at least 72 hours prior to dosing
- •b. If taking any supplement containing >20 mg of niacin, agrees to suspend use for the duration of the study
- •15. Have a positive urine drug test including Amphetamines, Barbiturates, Buprenorphine, Benzodiazepines, Cocaine, Cannabis, Methamphetamine, MDMA, Methadone, Opiates (Morphine, Oxycodone), Phencyclidine (PCP), and Tetrahydrocannabinol (THC). Exceptions are made for prescribed Benzodiazepines (stable dose for sleep or anxiety).
- •o Note: Benzodiazepine
研究者
相似试验
已完成
2 期
The Effect of Psilocybin on MDD Symptom Severity and Synaptic DensityMajor Depressive DisorderDepressionNCT04630964Section for Affective Disorders; Northern Stockholm Psychiatry35
已完成
1 期
PsiConnect: Brain Connectivity and Context under PsilocybinACTRN12621001375842Monash University60
已完成
2 期
Effects of Psilocybin in Major Depressive DisorderMajor Depressive DisorderNCT03181529Johns Hopkins University27
进行中（未招募）
1 期
Psilocybin's effects on anhedoniaMedDRA version: 23.0Level: LLTClassification code: 10083288Term: Clinical depression Class: 10037175MedDRA version: 24.0Level: LLTClassification code: 10056941Term: MRI brain Class: 10022891MedDRA version: 20.0Level: PTClassification code: 10002511Term: Anhedonia Class: 100000004873MedDRA version: 20.0Level: LLTClassification code: 10027942Term: Mood depression Class: 10037175MedDRA version: 21.1Level: PTClassification code: 10054976Term: Antidepressant therapy Class: 100000004865Major Depressive DisorderCTIS2023-509009-59-00Medical University of Vienna85
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-IECOMPASS Pathfinder, Limited216